Comparative drug screening in NUT midline carcinoma

[1]  J. Aster,et al.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma , 2014, Oncogene.

[2]  K. Carter,et al.  Novel BRD4–NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma , 2013, Oncogene.

[3]  P. Bamborough,et al.  Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. , 2013, Journal of medicinal chemistry.

[4]  Anne E Carpenter,et al.  The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling , 2013, Nature.

[5]  Shwu‐Yuan Wu,et al.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.

[6]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[7]  E. Estey,et al.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia , 2012, Haematologica.

[8]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[9]  Andrea K. Kukla,et al.  A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. , 2012, Gynecologic oncology.

[10]  J. Bradner,et al.  Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma , 2012, Clinical Cancer Research.

[11]  Jeffrey A Jones,et al.  ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. , 2012, Blood.

[12]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[13]  M. Ko,et al.  Activation of JNK Triggers Release of Brd4 from Mitotic Chromosomes and Mediates Protection from Drug-Induced Mitotic Stress , 2012, PloS one.

[14]  R. Prinjha,et al.  Place your BETs: the therapeutic potential of bromodomains. , 2012, Trends in pharmacological sciences.

[15]  S. Singer,et al.  The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial , 2012, Clinical Cancer Research.

[16]  John D. Roberts,et al.  Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies , 2012, Cancer Chemotherapy and Pharmacology.

[17]  C. French.  Pathogenesis of NUT midline carcinoma. , 2012, Annual review of pathology.

[18]  E. Verdin,et al.  Two-pronged Binding with Bromodomain-containing Protein 4 Liberates Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein Complexes* , 2011, The Journal of Biological Chemistry.

[19]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[20]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[21]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[22]  K. Lim,et al.  A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive‐disease small cell lung cancer , 2011, Cancer.

[23]  J. Aster,et al.  Differentiation of NUT midline carcinoma by epigenomic reprogramming. , 2011, Cancer research.

[24]  M. McDevitt,et al.  Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. , 2011, Blood.

[25]  C. French,et al.  NUT Midline Carcinoma in a Newborn with Multiorgan Disseminated Tumor and a 2-Year-Old with a Pancreatic/Hepatic Primary , 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[26]  R. Kratzke,et al.  Long-term survival of a patient with squamous cell carcinoma harboring NUT gene rearrangement. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[28]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[29]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[30]  A. Rice,et al.  T‐loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P‐TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes , 2010, Journal of cellular physiology.

[31]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[32]  Jeffrey A Jones,et al.  Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Gonen,et al.  Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors , 2009, Clinical Cancer Research.

[34]  M. Rubin,et al.  Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody , 2009, The American journal of surgical pathology.

[35]  Martin J Firth,et al.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism , 2009, British Journal of Cancer.

[36]  C. French.  Demystified molecular pathology of NUT midline carcinomas , 2008, Journal of Clinical Pathology.

[37]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[38]  F. Mertens,et al.  Successful treatment of a child with t(15;19)‐positive tumor , 2007, Pediatric blood & cancer.

[39]  Martin J Firth,et al.  In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia , 2007, British journal of haematology.

[40]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[41]  M. Dictor,et al.  Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy , 2006, BMC Cancer.

[42]  C. Cleeland,et al.  The role of statins in cancer therapy. , 2006, The oncologist.

[43]  J. Miyazaki,et al.  Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin. , 2005, Molecular biology of the cell.

[44]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[45]  C. Cordon-Cardo,et al.  A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol , 2005, Clinical Cancer Research.

[46]  J. Whitlock,et al.  Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Blagosklonny.  Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions , 2004, Cell cycle.

[48]  E. Newcomb.  Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity , 2004, Anti-cancer drugs.

[49]  G. Wilding,et al.  Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol , 2002, Cancer Chemotherapy and Pharmacology.

[50]  U. Kees,et al.  Medulloblastoma/primitive neuroectodermal tumour studied as a Matrigel enhanced subcutaneous xenograft model , 2001, Journal of Clinical Neuroscience.

[51]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Y. Ohtsuki,et al.  Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. , 1991, Cancer research.

[53]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[54]  U. Kees,et al.  Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). , 1991, The American journal of pediatric hematology/oncology.